These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23857432)

  • 1. Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line.
    Benabbou N; Mirshahi P; Cadillon M; Soria J; Therwath A; Mirshahi M
    Int J Oncol; 2013 Sep; 43(3):685-94. PubMed ID: 23857432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line.
    Benabbou N; Mirshahi P; Bordu C; Faussat AM; Tang R; Therwath A; Soria J; Marie JP; Mirshahi M
    Int J Oncol; 2014 Oct; 45(4):1372-80. PubMed ID: 25095896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
    Xu Y; Zhang J; Wu J; Zhong S; Li H
    Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
    Jernberg-Wiklund H; Nilsson K
    Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
    Eckstein N; Servan K; Hildebrandt B; Pölitz A; von Jonquières G; Wolf-Kümmeth S; Napierski I; Hamacher A; Kassack MU; Budczies J; Beier M; Dietel M; Royer-Pokora B; Denkert C; Royer HD
    Cancer Res; 2009 Apr; 69(7):2996-3003. PubMed ID: 19318572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
    Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
    Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF-1R anti-idiotypic antibody antagonist exhibited anti-ovarian cancer bioactivity and reduced cisplatin resistance.
    Weiwei Z; Ya X; Wenwen W; Jia J; Jing B; Ruitao Z; Chunfang W; Ruixia G
    Hum Cell; 2021 Jul; 34(4):1197-1214. PubMed ID: 33905103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of small interfering RNA targeting insulin-like growth factor-I receptor in ovarian cancer OVCAR3 cells.
    An Y; Cai Y; Guan Y; Cai L; Yang Y; Feng X; Zheng J
    Cancer Biother Radiopharm; 2010 Oct; 25(5):545-52. PubMed ID: 20950153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway.
    Dong L; Du M; Lv Q
    Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):753-760. PubMed ID: 31168597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.
    Vishwamitra D; Shi P; Wilson D; Manshouri R; Vega F; Schlette EJ; Amin HM
    Haematologica; 2011 Jun; 96(6):871-80. PubMed ID: 21330319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
    Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
    Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities.
    Deng Y; Wang Z; Zhang F; Qiao M; Yan Z; Wei Q; Wang J; Liu H; Fan J; Zou Y; Liao J; Hu X; Chen L; Yu X; Haydon RC; Luu HH; Qi H; He TC; Zhang J
    Cell Physiol Biochem; 2016; 39(3):871-88. PubMed ID: 27497986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.
    Park GB; Kim D
    Neoplasia; 2019 Feb; 21(2):206-215. PubMed ID: 30622051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
    Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
    Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of STAT3 activation by insulin-like growth factor I receptor.
    Zong CS; Chan J; Levy DE; Horvath C; Sadowski HB; Wang LH
    J Biol Chem; 2000 May; 275(20):15099-105. PubMed ID: 10747872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
    Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P
    Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells.
    Chua PJ; Lim JP; Guo TT; Khanna P; Hu Q; Bay BH; Baeg GH
    Int J Oncol; 2018 Dec; 53(6):2579-2589. PubMed ID: 30221675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
    Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
    Mol Cancer Ther; 2009 Aug; 8(8):2122-30. PubMed ID: 19638450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
    McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
    Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.